Probi 将来の成長

Future 基準チェック /46

Probi利益と収益がそれぞれ年間62%と5.3%増加すると予測されています。EPS は年間増加すると予想されています。自己資本利益率は 3 年後に3.1% 61.8%なると予測されています。

主要情報

62.0%

収益成長率

61.8%

EPS成長率

Biotechs 収益成長	45.0%
収益成長率	5.3%
将来の株主資本利益率	3.1%
アナリストカバレッジ	Low
最終更新日	22 Oct 2024

今後の成長に関する最新情報

Recent updates

Probi AB (publ)'s (STO:PROB) Price Is Right But Growth Is Lacking After Shares Rocket 31%

Nov 21

Probi's (STO:PROB) Anemic Earnings Might Be Worse Than You Think

Jul 24

There's No Escaping Probi AB (publ)'s (STO:PROB) Muted Revenues Despite A 43% Share Price Rise

Jun 26

Probi AB (publ)'s (STO:PROB) Intrinsic Value Is Potentially 19% Below Its Share Price

May 05

Is Probi AB (publ)'s (STO:PROB) Recent Price Movement Underpinned By Its Weak Fundamentals?

Mar 05

Here's Why I Think Probi (STO:PROB) Might Deserve Your Attention Today

Feb 15

Here's What Probi AB (publ)'s (STO:PROB) Shareholder Ownership Structure Looks Like

Jan 29

Probi AB (publ)'s (STO:PROB) Intrinsic Value Is Potentially 20% Below Its Share Price

Jan 11

Have Insiders Been Buying Probi AB (publ) (STO:PROB) Shares?

Dec 22

Has Probi AB (publ)'s (STO:PROB) Impressive Stock Performance Got Anything to Do With Its Fundamentals?

Dec 03

業績と収益の成長予測

OM:PROB - アナリストの将来予測と過去の財務データ ( )SEK Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	705	48	95	145	1
12/31/2025	667	33	78	131	1
12/31/2024	628	15	65	115	1
9/30/2024	630	11	76	132	N/A
6/30/2024	643	14	30	87	N/A
3/31/2024	608	-1	44	92	N/A
12/31/2023	628	17	31	86	N/A
9/30/2023	616	14	8	64	N/A
6/30/2023	605	20	62	119	N/A
3/31/2023	635	46	68	131	N/A
12/31/2022	618	41	91	156	N/A
9/30/2022	644	73	142	203	N/A
6/30/2022	658	79	77	132	N/A
3/31/2022	642	75	104	155	N/A
12/31/2021	658	83	112	154	N/A
9/30/2021	673	79	129	169	N/A
6/30/2021	709	93	164	207	N/A
3/31/2021	731	105	105	149	N/A
12/31/2020	717	93	100	143	N/A
9/30/2020	699	97	57	97	N/A
6/30/2020	645	85	87	132	N/A
3/31/2020	646	88	132	170	N/A
12/31/2019	626	86	138	174	N/A
9/30/2019	623	84	136	164	N/A
6/30/2019	650	90	128	143	N/A
3/31/2019	623	81	140	154	N/A
12/31/2018	604	76	114	128	N/A
9/30/2018	561	53	103	120	N/A
6/30/2018	525	34	N/A	98	N/A
3/31/2018	544	29	N/A	100	N/A
12/31/2017	612	69	N/A	146	N/A
9/30/2017	687	98	N/A	166	N/A
6/30/2017	643	117	N/A	136	N/A
3/31/2017	544	118	N/A	127	N/A
12/31/2016	443	102	N/A	90	N/A
9/30/2016	286	74	N/A	52	N/A
6/30/2016	248	60	N/A	74	N/A
3/31/2016	234	54	N/A	52	N/A
12/31/2015	216	49	N/A	62	N/A
9/30/2015	220	52	N/A	74	N/A
6/30/2015	205	46	N/A	56	N/A
3/31/2015	178	39	N/A	59	N/A
12/31/2014	135	22	N/A	37	N/A
9/30/2014	122	19	N/A	25	N/A
6/30/2014	109	16	N/A	27	N/A
3/31/2014	104	15	N/A	21	N/A
12/31/2013	104	15	N/A	25	N/A

アナリストによる今後の成長予測

収入対貯蓄率: PROBの予測収益成長率 (年間62% ) は貯蓄率 ( 1.2% ) を上回っています。

収益対市場: PROBの収益 ( 62% ) はSwedish市場 ( 15% ) よりも速いペースで成長すると予測されています。

高成長収益: PROBの収益は今後 3 年間で大幅に増加すると予想されています。

収益対市場: PROBの収益 ( 5.3% ) Swedish市場 ( -0.04% ) よりも速いペースで成長すると予測されています。

高い収益成長: PROBの収益 ( 5.3% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: PROBの自己資本利益率は、3年後には低くなると予測されています ( 3.1 %)。

Probi 将来の成長

Future 基準チェック /46

主要情報

今後の成長に関する最新情報

Probi AB (publ) Provides Earnings Guidance for the Third Quarter of 2022

Consensus EPS estimates fall to kr8.37

Price target increased to kr505

Price target raised to kr455

Recent updates

Probi AB (publ)'s (STO:PROB) Price Is Right But Growth Is Lacking After Shares Rocket 31%

New major risk - Share price stability

Now 27% overvalued after recent price rise

Probi AB (publ) Announces CFO Changes

Probi AB Launches Clinically-Supported Probiotic Solution for Metabolic Health at SupplySide West 2024

Third quarter 2024 earnings released: EPS: kr0.31 (vs kr0.56 in 3Q 2023)

Probi AB (Publ) Launches Probi Sense

New minor risk - Share price stability

Now 21% undervalued

Probi's (STO:PROB) Anemic Earnings Might Be Worse Than You Think

Second quarter 2024 earnings released: EPS: kr0.71 (vs kr0.55 loss in 2Q 2023)

Probi AB (publ) Strengthens the Gut-Brain Offering with New Study in Older Adults

There's No Escaping Probi AB (publ)'s (STO:PROB) Muted Revenues Despite A 43% Share Price Rise

Probi AB (publ) Approves Election of Stephanie Blum Sperisen as Board Member

Now 22% undervalued

Now 22% undervalued

Full year 2023 earnings: EPS exceeds analyst expectations

Now 21% undervalued

Dividend of kr1.30 announced

Now 21% undervalued after recent price drop

Probi AB (publ) to Report Fiscal Year 2024 Results on Jan 28, 2025

Full year 2023 earnings: EPS exceeds analyst expectations

Probi AB (Publ) Proposes Dividend for the Fiscal Year 2023

Probi AB (publ) to Report Q3, 2024 Results on Oct 22, 2024

Probi AB (publ), Annual General Meeting, May 07, 2024

Third quarter 2023 earnings released: EPS: kr0.56 (vs kr1.09 in 3Q 2022)

Probi AB (Publ) Appoints Per Lindblad as New CFO, Effective from 1st of November, 2023

Probi Launches Two New Concepts Together with Clasado Biosciences at Supply Side West

Second quarter 2023 earnings released: kr0.55 loss per share (vs kr1.75 profit in 2Q 2022)

Probi AB (Publ) Announces Resignation of Henrik Lundkvist as Chief Financial Officer

Insufficient new directors

Upcoming dividend of kr1.30 per share at 0.7% yield

Full year 2022 earnings: EPS and revenues miss analyst expectations

Probi AB (publ) to Report Fiscal Year 2022 Final Results on Apr 04, 2023

Full year 2022 earnings: EPS and revenues miss analyst expectations

Probi AB (Publ) Proposes Dividend for the 2022 Financial Year, Payable on May 11, 2023

Now 24% undervalued after recent price drop

Now 20% undervalued after recent price drop

Probi AB (publ) to Report Q2, 2023 Results on Jul 18, 2023

Now 21% undervalued after recent price drop

Probi AB (publ) Announces Management Changes

Now 25% undervalued after recent price drop

Probi Probiotics Reduce Gut Problems in Connection with Cancer Radiotherapy

Now 21% undervalued after recent price drop

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Probi AB (publ) Provides Earnings Guidance for the Third Quarter of 2022

Investor sentiment deteriorated over the past week

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Probi AB (Publ) Approves Dividend for the Financial Year 2021

Chief Executive Officer recently bought kr409k worth of stock

Upcoming dividend of kr1.30 per share

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Probi AB (Publ) Proposes Dividend, Payable on 12 May 2022

Now 23% undervalued after recent price drop

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Probi AB (Publ) Proposes Dividend for the Year 2021

Third quarter 2021 earnings released: EPS kr1.62 (vs kr2.91 in 3Q 2020)

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Should You Be Adding Probi (STO:PROB) To Your Watchlist Today?

Estimating The Intrinsic Value Of Probi AB (publ) (STO:PROB)

Consensus EPS estimates fall to kr8.37

Second quarter 2021 earnings released: EPS kr1.39 (vs kr2.37 in 2Q 2020)

Investor sentiment improved over the past week

Is Now The Time To Put Probi (STO:PROB) On Your Watchlist?

Probi AB (publ)'s (STO:PROB) Intrinsic Value Is Potentially 19% Below Its Share Price

Upcoming dividend of kr1.10 per share

Price target increased to kr505